1.
Mohanty SK, Satapathy A, Naidu
MM, Mukhopadhyay S, Sharma S, Barton LM, Stroberg E, Duval EJ, Pradhan D,
Tzankov A, Parwani AV. Severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology
perspective on current knowledge. Diagn Pathol. 2020 Aug 14;15(1):103. doi:
10.1186/s13000-020-01017-8.
2.
Elezkurtaj S, Greuel S, Ihlow
J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M, Hauptmann K,
Ingold-Heppner B, Miller F, Herbst H, Corman VM, Martin H, Radbruch H, Heppner
FL, Horst D. Causes of death and comorbidities in hospitalized patients with
COVID-19. Sci Rep. 2021 Feb 19;11(1):4263. doi:
10.1038/s41598-021-82862-5.
3.
Wichmann D, Sperhake JP,
Lütgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep
I, Schröder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S,
Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S,
Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Püschel K, Kluge S.
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A
Prospective Cohort Study. Ann Intern Med. 2020 Aug 18;173(4):268-277. doi:
10.7326/M20-2003.
4.
Chauhan S. Comprehensive review
of coronavirus disease 2019 (COVID-19). Biomed J. 2020 Aug;43(4):334-340. doi:
10.1016/j.bj.2020.05.023.
5.
Al-Rohaimi AH, Al Otaibi F.
Novel SARS-CoV-2 outbreak and COVID19 disease; a systemic review on the global
pandemic. Genes Dis. 2020 Jun 17;7(4):491-501. doi:
10.1016/j.gendis.2020.06.004.
6.
Wu,
W., Cheng, Y., Zhou, H. et al. The
SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure
and functions, and use as a potential target in the development of vaccines and
diagnostics. Virol J 20, 6 (2023). https://doi.org/10.1186/s12985-023-01968-6
7.
Robinson EL, Alkass K, Bergmann
O, Maguire JJ, Roderick HL, Davenport AP. Genes encoding ACE2, TMPRSS2 and
related proteins mediating SARS-CoV-2 viral entry are upregulated with age in
human cardiomyocytes. J Mol Cell Cardiol. 2020 Oct;147:88-91. doi: 10.1016/j.yjmcc.2020.08.009.
8.
Cucinotta D, Vanelli M. WHO
Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar 19;91(1):157-160. doi:
10.23750/abm.v91i1.9397.
9.
Carfora V, Spiniello G,
Ricciolino R, Di Mauro M, Migliaccio MG, Mottola FF, Verde N, Coppola N;
Vanvitelli COVID-19 group. Anticoagulant treatment in COVID-19: a narrative
review. J Thromb Thrombolysis. 2021 Apr;51(3):642-648. doi:
10.1007/s11239-020-02242-0.
10.
Park SE. Epidemiology,
virology, and clinical features of severe acute respiratory syndrome
-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 2020
Apr;63(4):119-124. doi: 10.3345/cep.2020.00493.
11.
Farkaš B, Minneci M, Misevicius
M, Rozas I. A Tale of Two Proteases: MPro and TMPRSS2 as
Targets for COVID-19 Therapies. Pharmaceuticals (Basel). 2023 Jun 2;16(6):834.
doi: 10.3390/ph16060834.
12.
Moschonas IC, Tselepis AD.
SARS-CoV-2 infection and thrombotic complications: a narrative review. J Thromb
Thrombolysis. 2021 Jul;52(1):111-123. doi: 10.1007/s11239-020-02374-3.
13.
Garmo C, Bajwa T, Burns B.
Physiology, Clotting Mechanism. [Updated 2023 Sep 4]. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2025
Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507795/
14.
Barmore W, Bajwa T, Burns B.
Biochemistry, Clotting Factors. [Updated 2023 Feb 24]. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2025
Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507850/
15.
Akhter MS, Hamali HA, Mobarki
AA, Rashid H, Oldenburg J, Biswas A. SARS-CoV-2 Infection: Modulator of
Pulmonary Embolism Paradigm. J Clin Med. 2021 Mar 4;10(5):1064. doi:
10.3390/jcm10051064.
16.
De Lorenzo A, Escobar S,
Tibiriçá E. Systemic endothelial dysfunction: A common pathway for COVID-19,
cardiovascular and metabolic diseases. Nutr Metab Cardiovasc Dis. 2020 Jul
24;30(8):1401-1402. doi: 10.1016/j.numecd.2020.05.007.
17.
Lampelj M, Arko D, Cas-Sikosek
N, Kavalar R, Ravnik M, Jezersek-Novakovic B, Dobnik S, Dovnik NF, Takac I.
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor
type-1 (PAI-1) in breast cancer - correlation with traditional prognostic
factors. Radiol Oncol. 2015 Nov 27;49(4):357-64. doi:
10.2478/raon-2014-0049.
18.
Meizoso JP, Moore HB, Moore EE.
Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular
Mechanisms, and Therapeutic Implications. J Am Coll Surg. 2021
Jun;232(6):995-1003. doi: 10.1016/j.jamcollsurg.2021.02.019
19.
Al-Ani F, Chehade S,
Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping
review. Thromb Res. 2020 Aug;192:152-160. doi: 10.1016/j.thromres.2020.05.039.
20.
Lee KW, Yusof Khan AHK, Ching
SM, Chia PK, Loh WC, Abdul Rashid AM, Baharin J, Inche Mat LN, Wan Sulaiman WA,
Devaraj NK, Sivaratnam D, Basri H, Hoo FK. Stroke and Novel Coronavirus
Infection in Humans: A Systematic Review and Meta-Analysis. Front Neurol. 2020
Oct 6;11:579070. doi: 10.3389/fneur.2020.579070.
21.
Hanson PJ, Liu-Fei F, Ng C,
Minato TA, Lai C, Hossain AR, Chan R, Grewal B, Singhera G, Rai H, Hirota J,
Anderson DR, Radio SJ, McManus BM. Characterization of COVID-19-associated
cardiac injury: evidence for a multifactorial disease in an autopsy cohort. Lab
Invest. 2022 Aug;102(8):814-825. doi: 10.1038/s41374-022-00783-x.
22.
Lee PY, Cron RQ. The
Multifaceted Immunology of Cytokine Storm Syndrome. J Immunol. 2023 Apr
15;210(8):1015-1024. doi: 10.4049/jimmunol.2200808.
23.
Danish FI, Rabani AE, Subhani
FE, Yasmin S, Koul SS. COVID-19: Vaccine-induced immune thrombotic
thrombocytopenia. Eur J Haematol. 2022 Dec;109(6):619-632. doi:
10.1111/ejh.13855.
24.
Ashworth I, Thielemans L,
Chevassut T. Thrombocytopenia: the good, the bad and the ugly. Clin Med (Lond).
2022 May;22(3):214-217. doi: 10.7861/clinmed.2022-0146.
25.
Gabarin
N, Arnold DM, Nazy I, Warkentin TE. Treatment of
vaccine-induced immune thrombotic thrombocytopenia (VITT). Semin Hematol. 2022
Apr;59(2):89-96. doi: 10.1053/j.seminhematol.2022.03.002. Epub 2022 Mar
7.
26.
Nicholson M, Goubran H, Chan N,
Siegal D. No apparent association between mRNA COVID-19 vaccination and venous
thromboembolism. Blood Rev. 2022 Nov;56:100970. doi:
10.1016/j.blre.2022.100970.
27.
McGonagle D, De Marco G,
Bridgewood C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic
Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. J Autoimmun.
2021 Jul;121:102662. doi: 10.1016/j.jaut.2021.102662.
28.
Trougakos IP, Terpos E,
Alexopoulos H, Politou M, Paraskevis D, Scorilas A, Kastritis E, Andreakos E,
Dimopoulos MA. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis.
Trends Mol Med. 2022 Jul;28(7):542-554. doi: 10.1016/j.molmed.2022.04.007.
29.
Chen Z, Xu W, Ma W, Shi X, Li
S, Hao M, Fang Y, Zhang L. Clinical laboratory evaluation of COVID-19. Clin
Chim Acta. 2021 Aug;519:172-182. doi: 10.1016/j.cca.2021.04.022.
30.
Di Minno A, Ambrosino P,
Calcaterra I, Di Minno MND. COVID-19 and Venous Thromboembolism: A
Meta-analysis of Literature Studies. Semin Thromb Hemost. 2020
Oct;46(7):763-771. doi: 10.1055/s-0040-1715456.
31.
Sutanto H, Soegiarto G. Risk of
Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic
Approach, and Management. Hematol Rep. 2023 Apr 3;15(2):225-243. doi:
10.3390/hematolrep15020024.
32.
Middeldorp S, Coppens M, van
Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS,
Heijmans J, Smits LP, Bonta PI, van Es N. Incidence of venous thromboembolism
in hospitalized patients with COVID-19. J Thromb Haemost. 2020
Aug;18(8):1995-2002. doi: 10.1111/jth.14888.
33.
Barnett N, Leith D, Govind D,
Ramnani V, Williamson H, Chung J, Drebes A. Prevalence of pulmonary embolism
and deep venous thrombosis during the COVID-19 pandemic in an intensive care
unit cohort: a service evaluation. Br J Anaesth. 2022 Nov;129(5):e124-e126.
doi: 10.1016/j.bja.2022.07.040.
34.
Katsoularis I,
Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, Lindmark
K, Fors Connolly AM. Risks of deep vein thrombosis, pulmonary embolism, and
bleeding after covid-19: nationwide self-controlled cases series and matched
cohort study. BMJ. 2022 Apr 6;377:e069590. doi: 10.1136/bmj-2021-069590.
35.
Ali MAM, Spinler SA. COVID-19
and thrombosis: From bench to bedside. Trends Cardiovasc Med. 2021
Apr;31(3):143-160. doi: 10.1016/j.tcm.2020.12.004.
36.
Mostaza-Fernández JL, Guerra
Laso J, Carriedo Ule D, Ruiz de Morales JM. Hemophagocytic lymphohistiocytosis
associated with viral infections: Diagnostic challenges and therapeutic
dilemmas. Rev Clin Esp (Barc). 2014 Aug-Sep;214(6):320-7. doi: 10.1016/j.rce.2014.03.009.
37.
Valade S, Joly BS, Veyradier A,
Fadlallah J, Zafrani L, Lemiale V, Launois A, Stepanian A, Galicier L, Fieschi
C, Mirouse A, Tudesq JJ, Lepretre AC, Azoulay E, Darmon M, Mariotte E.
Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis.
PLoS One. 2021 Aug 3;16(8):e0251216. doi: 10.1371/journal.pone.0251216.
38.
Moores LK, Tritschler T,
Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Iaccarino J, Jimenez
D, LeGal G, Rali P, Wells P. Thromboprophylaxis in Patients With COVID-19: A
Brief Update to the CHEST Guideline and Expert Panel Report. Chest. 2022
Jul;162(1):213-225. doi: 10.1016/j.chest.2022.02.006.
39.
Yan, Z.; Yang, M.; Lai, C.-L.
Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ
Systems and Recommendation on Rehabilitation Plans. Biomedicines 2021, 9,
966. https://doi.org/10.3390/biomedicines9080966
40.
Nutescu EA, Burnett A, Fanikos
J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the
treatment of venous thromboembolism. J Thromb Thrombolysis. 2016
Jan;41(1):15-31. doi: 10.1007/s11239-015-1314-3.
41.
Cuker A, Tseng EK, Nieuwlaat R,
Angchaisuksiri P, et al. American Society of Hematology living guidelines on
the use of anticoagulation for thromboprophylaxis in patients with COVID-19:
May 2021 update on the use of intermediate-intensity anticoagulation in
critically ill patients. Blood Adv. 2021 Oct 26;5(20):3951-3959. doi:
10.1182/bloodadvances.2021005493.
42.
Borawski J, Gozdzikiewicz J,
Dubowski M, Pawlak K, Mysliwiec M. Tissue factor pathway inhibitor release and
depletion by sulodexide in humans. Adv Med Sci. 2009;54(1):32-6. doi:
10.2478/v10039-009-0009-4.
43.
Gresele P, Momi S, Falcinelli
E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol.
2011 Oct;72(4):634-46. doi: 10.1111/j.1365-2125.2011.04034.x.
44.
Kim HH, Liao JK. Translational
therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008
Mar;28(3):s39-42. doi: 10.1161/ATVBAHA.107.160226.
45.
Khimani F, Wolf AJ, Yoon B,
Blancke A, Gerhart C, Endsley D, Dougherty A, Ray AK, Yango AF, Flynn SD, Lip
GYH, Gonzalez SA, Sathyamoorthy M. Therapeutic considerations for prevention
and treatment of thrombotic events in COVID-19. Thromb Update. 2023 Mar;10:100126.
doi: 10.1016/j.tru.2022.100126.
46.
Herbert JM, Savi P. P2Y12, a
new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003
May;3(2):113-22. doi: 10.1055/s-2003-40669.
47.
Lam S, Tran T. Vorapaxar: A
Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
Cardiol Rev. 2015 Sep-Oct;23(5):261-7. doi: 10.1097/CRD.0000000000000075.
48.
Tomaiuolo M, Brass LF, Stalker
TJ. Regulation of Platelet Activation and Coagulation and Its Role in Vascular
Injury and Arterial Thrombosis. Interv Cardiol Clin. 2017 Jan;6(1):1-12. doi:
10.1016/j.iccl.2016.08.001.
49.
Cardenas JC, Wang YW, Karri JV,
Vincent S, Cap AP, Cotton BA, Wade CE. Supplementation with antithrombin III ex
vivo optimizes enoxaparin responses in critically injured patients. Thromb Res.
2020 Mar;187:131-138. doi: 10.1016/j.thromres.2020.01.014.
50.
Koster A, Fischer KG, Harder S,
Mertzlufft F. The direct thrombin inhibitor argatroban: a review of its use in
patients with and without HIT. Biologics. 2007 Jun;1(2):105-12.
51.
Ramacciotti E, Barile Agati L,
Calderaro D, Aguiar VCR, Spyropoulos AC, de Oliveira CCC, Lins Dos Santos J,
Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, da Fonseca BAL,
Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, de Almeida Araujo Ramos K, de
Moraes NF, Tierno PFGMM, de Oliveira ALML, Tachibana A, Chate RC, Santos MVB,
de Menezes Cavalcante BB, Moreira RCR, Chang C, Tafur A, Fareed J, Lopes RD;
MICHELLE investigators. Rivaroxaban versus no anticoagulation for
post-discharge thromboprophylaxis after hospitalisation for COVID-19
(MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet.
2022 Jan 1;399(10319):50-59. doi: 10.1016/S0140-6736(21)02392-8.
52.
Connors JM, Brooks MM, Sciurba
FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan BA, Eng H, Martin
D, Zaharris E, Everett B, Castro L, Shapiro NL, Lin JY, Hou PC, Pepine CJ,
Handberg E, Haight DO, Wilson JW, Majercik S, Fu Z, Zhong Y, Venugopal V, Beach
S, Wisniewski S, Ridker PM; ACTIV-4B Investigators. Effect of Antithrombotic
Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic
COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA. 2021 Nov
2;326(17):1703-1712. doi: 10.1001/jama.2021.17272.
53.
Loftis LL, Meals EA, English
BK. Differential effects of pentoxifylline and interleukin-10 on production of
tumor necrosis factor and inducible nitric oxide synthase by murine
macrophages. J Infect Dis. 1997 Apr;175(4):1008-11. doi: 10.1086/513960.
54.
Dechamps, M.; De Poortere, J.;
Octave, M.; Ginion, A.; Robaux, V.; Pirotton, L.; Bodart, J.; Gruson, D.; Van
Dievoet, M.-A.; Douxfils, J.; et al. Dexamethasone Modulates the Cytokine
Response but Not COVID-19-Induced Coagulopathy in Critically Ill. Int.
J. Mol. Sci. 2023, 24, 7278. https://doi.org/10.3390/ijms24087278
55.
Wu Z, McGoogan JM.
Characteristics of and important lessons from the coronavirus disease 2019
(COVID-19) outbreak in China: summary of a report of 72 314 cases from the
Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-1242.
56.
Khimani F, Wolf AJ, Yoon B,
Blancke A, Gerhart C, Endsley D, Dougherty A, Ray AK, Yango AF, Flynn SD, Lip
GYH, Gonzalez SA, Sathyamoorthy M. Therapeutic considerations for prevention
and treatment of thrombotic events in COVID-19. Thromb Update. 2023 Mar;10:100126.
doi: 10.1016/j.tru.2022.100126.
57.
Lee
KCH, Sewa DW, Phua GC. Potential role of statins in
COVID-19. Int J Infect Dis. 2020 Jul;96:615-617. doi:
10.1016/j.ijid.2020.05.115.
58.
Lim EHT, van Amstel RBE, de
Boer VV, van Vught LA, de Bruin S, Brouwer MC, Vlaar APJ, van de Beek D.
Complement activation in COVID-19 and targeted therapeutic options: A scoping
review. Blood Rev. 2023 Jan;57:100995. doi: 10.1016/j.blre.2022.100995.
59.
Trambas, I.A.; Coughlan, M.T.;
Tan, S.M. Therapeutic Potential of Targeting Complement C5a Receptors in
Diabetic Kidney Disease. Int. J. Mol. Sci. 2023, 24,
8758. https://doi.org/10.3390/ijms24108758
60.
Afzali B, Noris M, Lambrecht
BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022
Feb;22(2):77-84. doi: 10.1038/s41577-021-00665-1.
61.
Annamaraju P, Patel P, Baradhi
KM. Pentoxifylline. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure
Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559096/
62.
Broderick C, Forster R,
Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication.
Cochrane Database Syst Rev. 2020 Oct 16;10(10):CD005262. doi:
10.1002/14651858.CD005262.
63.
Maldonado V, Loza-Mejía MA,
Chávez-Alderete J. Repositioning of pentoxifylline as an immunomodulator and
regulator of the renin-angiotensin system in the treatment of COVID-19. Med
Hypotheses. 2020 Nov;144:109988. doi: 10.1016/j.mehy.2020.109988.
64.
Hendry BM, Stafford N, Arnold
AD, Sangwaiya A, Manglam V, Rosen SD, Arnold J. Hypothesis: Pentoxifylline is a
potential cytokine modulator therapeutic in COVID-19 patients. Pharmacol Res
Perspect. 2020 Aug;8(4):e00631. doi: 10.1002/prp2.631.
65.
Ciszewicz M, Polubinska A,
Antoniewicz A, Suminska-Jasinska K, Breborowicz A. Sulodexide suppresses
inflammation in human endothelial cells and prevents glucose cytotoxicity.
Transl Res. 2009 Mar;153(3):118-23. doi: 10.1016/j.trsl.2008.12.007.
66.
Gonzalez-Ochoa A, Hernandez A,
Raffetto J. Sulodexide in the Treatment of Early Stages of COVID-19. J Vasc
Surg Venous Lymphat Disord. 2021 Mar;9(2):539. doi: 10.1016/j.jvsv.2020.12.012.
67.
Gonzalez-Ochoa AJ, Szolnoky G,
Hernandez-Ibarra AG, Fareed J. Treatment with Sulodexide Downregulates
Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients. Clin
Appl Thromb Hemost. 2025 Jan-Dec;31:10760296241297647. doi: 10.1177/10760296241297647.
68.
De Schryver EL, Algra A, van
Gijn J. Dipyridamole for preventing stroke and other vascular events in
patients with vascular disease. Cochrane Database Syst Rev. 2003;(1):CD001820.
doi: 10.1002/14651858.CD001820. Update in: Cochrane Database Syst Rev. 2006 Apr
19;(2):CD001820. doi: 10.1002/14651858.
69.
Gresele P, Momi S, Falcinelli
E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol.
2011 Oct;72(4):634-46. doi: 10.1111/j.1365-2125.2011.04034.x.
70.
Wennmalm A. Endothelial nitric
oxide and cardiovascular disease. J Intern Med. 1994 Apr;235(4):317-27. doi:
10.1111/j.1365-2796.1994.tb01081.x.
71.
Li Z, Luo W, Fang S, Chen X,
Lin T, Zhou S, Zhang L, Yang W, Li Z, Ye J, Wang J, Liu P, Li Z. Prostacyclin
facilitates vascular smooth muscle cell phenotypic transformation via
activating TP receptors when IP receptors are deficient. Acta Physiol (Oxf). 2021
Feb;231(2):e13555. doi: 10.1111/apha.13555.
72.
Xu X, Chen Y, Lu X, Zhang W,
Fang W, Yuan L, Wang X. An update on inhibitors targeting RNA-dependent RNA
polymerase for COVID-19 treatment: Promises and challenges. Biochem Pharmacol.
2022 Nov;205:115279. doi: 10.1016/j.bcp.2022.115279.
73.
Ornelas A, Zacharias-Millward
N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya
P, Millward S. Beyond COX-1: the effects of aspirin on platelet biology and
potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017
Jun;36(2):289-303. doi: 10.1007/s10555-017-9675-z.
74.
Di Bella S, Luzzati R, Principe
L, Zerbato V, Meroni E, Giuffrè M, Crocè LS, Merlo M, Perotto M, Dolso E,
Maurel C, Lovecchio A, Dal Bo E, Lagatolla C, Marini B, Ippodrino R, Sanson G.
Aspirin and Infection: A Narrative Review. Biomedicines. 2022 Jan 25;10(2):263.
doi: 10.3390/biomedicines10020263.
75.
Tung
YT, Wei CH, Yen CC, Lee PY, Ware LB, Huang HE, Chen W, Chen CM. Aspirin Attenuates Hyperoxia-Induced Acute Respiratory Distress
Syndrome (ARDS) by Suppressing Pulmonary Inflammation via the NF-κB Signaling
Pathway. Front Pharmacol. 2022 Jan 17;12:793107. doi:
10.3389/fphar.2021.793107.
76.
Ortiz-Muñoz G, Mallavia B, Bins
A, Headley M, Krummel MF, Looney MR. Aspirin-triggered 15-epi-lipoxin A4
regulates neutrophil-platelet aggregation and attenuates acute lung injury in
mice. Blood. 2014 Oct 23;124(17):2625-34. doi: 10.1182/blood-2014-03-562876.
77.
Beavers CJ, Naqvi IA.
Clopidogrel. [Updated 2023 Jul 10]. In: StatPearls [Internet]. Treasure Island
(FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470539/
78.
Morrow DA, Alberts MJ, Mohr JP,
Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E;
Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic
Ischemic Events–TIMI 50 Steering Committee and Investigators. Efficacy and
safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013
Mar;44(3):691-8. doi: 10.1161/STROKEAHA.111.000433.
79.
Rivera J, Lozano ML,
Navarro-Núñez L, Vicente V. Platelet receptors and signaling in the dynamics of
thrombus formation. Haematologica. 2009 May;94(5):700-11. doi:
10.3324/haematol.2008.003178.
80.
van Hinsbergh VW.
Endothelium--role in regulation of coagulation and inflammation. Semin
Immunopathol. 2012 Jan;34(1):93-106. doi: 10.1007/s00281-011-0285-5.
81.
Mondal S, Quintili AL,
Karamchandani K, Bose S. Thromboembolic disease in COVID-19 patients: A brief
narrative review. J Intensive Care. 2020 Sep 14;8:70. doi:
10.1186/s40560-020-00483-y.
82.
Kruuse C, Jacobsen TB, Thomsen
LL, Hasselbalch SG, Frandsen EK, Dige-Petersen H, Olesen J. Effects of the
non-selective phosphodiesterase inhibitor pentoxifylline on regional cerebral
blood flow and large arteries in healthy subjects. Eur J Neurol. 2000 Nov;7(6):629-38.
doi: 10.1046/j.1468-1331.2000.00116.x.
83.
Makarem A, Zareef R, Abourjeili
J, Nassar JE, Bitar F, Arabi M. Low molecular weight heparin in COVID-19:
benefits and concerns. Front Pharmacol. 2023 Apr 27;14:1159363. doi:
10.3389/fphar.2023.1159363.
84.
Bikdeli B, Talasaz AH, Rashidi
F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, Sezavar H, Dabbagh A,
Beigmohammadi MT, Payandemehr P, Yadollahzadeh M, Riahi T, Khalili H,
Jamalkhani S, Rezaeifar P, Abedini A, Lookzadeh S, Shahmirzaei S, Tahamtan O,
Matin S, Amin A, Parhizgar SE, Jimenez D, Gupta A, Madhavan MV, Parikh SA,
Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Mohebbi B, Piazza
G, Kirtane AJ, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Intermediate
versus standard-dose prophylactic anticoagulation and statin therapy versus
placebo in critically-ill patients with COVID-19: Rationale and design of the
INSPIRATION/INSPIRATION-S studies. Thromb Res. 2020 Dec;196:382-394. doi:
10.1016/j.thromres.2020.09.027.
85.
Talasaz AH, Sadeghipour P,
Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, Gheymati
A, Ariannejad H, Hosseini SH, Jamalkhani S, Sholzberg M, Monreal M, Jimenez D,
Piazza G, Parikh SA, Kirtane AJ, Eikelboom JW, Connors JM, Hunt BJ, Konstantinides
SV, Cushman M, Weitz JI, Stone GW, Krumholz HM, Lip GYH, Goldhaber SZ, Bikdeli
B. Recent Randomized Trials of Antithrombotic Therapy for
Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll
Cardiol. 2021 Apr 20;77(15):1903-1921. doi: 10.1016/j.jacc.2021.02.035.
86.
Farkouh ME, Stone GW, Lala A,
Bagiella E, Moreno PR, Nadkarni GN, Ben-Yehuda O, Granada JF, Dressler O,
Tinuoye EO, Granada C, Bustamante J, Peyra C, Godoy LC, Palacios IF, Fuster V.
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
J Am Coll Cardiol. 2022 Mar 8;79(9):917-928. doi: 10.1016/j.jacc.2021.12.023.
87.
Bais B, Sozio E, De Silvestri
D, Volpetti S, Zannier ME, Filì C, Bassi F, Alcaro L, Cotrufo M, Pagotto A,
Giacinta A, Patruno V, Da Porto A, Sbrojavacca R, Curcio F, Tascini C, Sechi
LA, Colussi G. Effect of heparin treatment on pulmonary embolism and in-hospital
death in unvaccinated COVID-19 patients without overt deep vein thrombosis.
Thromb J. 2022 Jun 20;20(1):34. doi: 10.1186/s12959-022-00393-z.
88.
Frise MC, Gates REV, Curry NS,
Danbury CM. Successful Use of Argatroban to Treat a Critically Ill Patient with
Coagulopathy and Nephropathy Secondary to COVID-19. TH Open. 2020 Dec
15;4(4):e400-e402. doi: 10.1055/s-0040-1721501.
89.
Chen A, Stecker E, A Warden B.
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges.
J Am Heart Assoc. 2020 Jul 7;9(13):e017559. doi: 10.1161/JAHA.120.017559.
90.
García-Escobar I,
Brozos-Vázquez E, Gutierrez Abad D, Martínez-Marín V, Pachón V, Muñoz Martín
AJ; Cancer and Thrombosis Section of the Spanish Society of Medical Oncology
(SEOM). Direct oral anticoagulants for the treatment and prevention of venous
thromboembolism in patients with cancer: current evidence. Clin Transl Oncol.
2021 Jun;23(6):1034-1046. doi: 10.1007/s12094-020-02506-4.
91.
Julia S, James U. Direct Oral
Anticoagulants: A Quick Guide. Eur Cardiol. 2017 Aug;12(1):40-45. doi:
10.15420/ecr.2017:11:2.
92.
Giles AJ, Hutchinson MND,
Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D,
Reid CM, Park DM, Gilbert MR. Dexamethasone-induced immunosuppression:
mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 Jun 11;6(1):51.
doi: 10.1186/s40425-018-0371-5.
93.
RECOVERY Collaborative Group;
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D,
Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan
K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized
Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi:
10.1056/NEJMoa2021436.
94.
WHO Rapid Evidence Appraisal
for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV,
Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti
AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A,
Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge
A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A,
Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association
Between Administration of Systemic Corticosteroids and Mortality Among
Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct
6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
95.
Michot JM, Albiges L, Chaput N,
Saada V, Pommeret F, Griscelli F, Balleyguier C, Besse B, Marabelle A, Netzer
F, Merad M, Robert C, Barlesi F, Gachot B, Stoclin A. Tocilizumab, an anti-IL-6
receptor antibody, to treat COVID-19-related respiratory failure: a case
report. Ann Oncol. 2020 Jul;31(7):961-964. doi: 10.1016/j.annonc.2020.03.300.
96.
Levi M. Tocilizumab for severe
COVID-19: A promising intervention affecting inflammation and coagulation. Eur
J Intern Med. 2020 Jun;76:21-22. doi: 10.1016/j.ejim.2020.05.018.
97.
Sobue S, Nomura T, Ishikawa T,
Ito S, Saso K, Ohara H, Joh T, Itoh M, Kakumu S. Th1/Th2 cytokine profiles and
their relationship to clinical features in patients with chronic hepatitis C
virus infection. J Gastroenterol. 2001 Aug;36(8):544-51. doi: 10.1007/s005350170057.
98.
Sageshima J, Ciancio G, Chen L,
Burke GW 3rd. Anti-interleukin-2 receptor antibodies-basiliximab and
daclizumab-for the prevention of acute rejection in renal transplantation.
Biologics. 2009;3:319-36. doi: 10.2147/btt.2009.3257.
99.
Yamaguchi A, Botta E, Holinstat
M. Eicosanoids in inflammation in the blood and the vessel. Front Pharmacol.
2022 Sep 27;13:997403. doi: 10.3389/fphar.2022.997403.
100.
Friedman EA, Ogletree ML,
Haddad EV, Boutaud O. Understanding the role of prostaglandin E2 in regulating
human platelet activity in health and disease. Thromb Res. 2015
Sep;136(3):493-503. doi: 10.1016/j.thromres.2015.05.027.
101.
Takeda T, Hoshida S, Nishino M,
Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin
and angiotensin II modulators on high-sensitive C-reactive protein levels.
Atherosclerosis. 2003 Jul;169(1):155-8. doi: 10.1016/s0021-9150(03)00158-8.
102.
Artola RT, Mihos CG, Santana O.
Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus. South
Med J. 2016 Nov;109(11):705-711. doi: 10.14423/SMJ.0000000000000561.
103.
Esmon CT. The interactions
between inflammation and coagulation. Br J Haematol. 2005 Nov;131(4):417-30.
doi: 10.1111/j.1365-2141.2005.05753.x.
104.
Acharya
D, Liu G, Gack MU. Dysregulation of type I interferon
responses in COVID-19. Nat Rev Immunol. 2020 Jul;20(7):397-398. doi:
10.1038/s41577-020-0346-x.
105.
Salimi-Jeda A, Abbassi S,
Mousavizadeh A, Esghaie M, Bokharaei-Salim F, Jeddi F, Shafaati M, Abdoli A.
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune
responses, potential therapeutic, and vaccine development strategies. Int
Immunopharmacol. 2021 Dec;101(Pt A):108232. doi: 10.1016/j.intimp.2021.108232.
106.
Subramaniam S, Ogoti Y,
Hernandez I, Zogg M, Botros F, Burns R, DeRousse JT, Dockendorff C, Mackman N,
Antoniak S, Fletcher C, Weiler H. A thrombin-PAR1/2 feedback loop amplifies
thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C).
Blood Adv. 2021 Jul 13;5(13):2760-2774. doi: 10.1182/bloodadvances.2021004360.
107.
Mackman N. Role of tissue
factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb
Vasc Biol. 2004 Jun;24(6):1015-22. doi: 10.1161/01.ATV.0000130465.23430.74.
108.
Udovicic I, Stanojevic I,
Djordjevic D, Zeba S, Rondovic G, Abazovic T, Lazic S, Vojvodic D, To K,
Abazovic D, Khan W, Surbatovic M. Immunomonitoring of Monocyte and Neutrophil
Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. J
Clin Med. 2021 Dec 12;10(24):5815. doi: 10.3390/jcm10245815.
109.
Bernard, I.; Limonta, D.;
Mahal, L.K.; Hobman, T.C. Endothelium Infection and Dysregulation by
SARS-CoV-2: Evidence and Caveats in COVID-19. Viruses 2021, 13,
29. https://doi.org/10.3390/v13010029
110.
Won T, Wood MK, Hughes DM,
Talor MV, Ma Z, Schneider J, Skinner JT, Asady B, Goerlich E, Halushka MK, Hays
AG, Kim DH, Parikh CR, Rosenberg AZ, Coppens I, Johns RA, Gilotra NA, Hooper
JE, Pekosz A, Čiháková D. Endothelial thrombomodulin downregulation caused by
hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient
lungs. EBioMedicine. 2022 Jan;75:103812. doi: 10.1016/j.ebiom.2022.103812.
111.
Wang J, Pendurthi UR, Yi G, Rao
LVM. SARS-CoV-2 infection induces the activation of tissue factor-mediated
coagulation via activation of acid sphingomyelinase. Blood. 2021 Jul
29;138(4):344-349. doi: 10.1182/blood.2021010685
112.
Nawroth PP, Handley DA, Esmon
CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while
suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A. 1986
May;83(10):3460-4. doi: 10.1073/pnas.83.10.3460.
113.
May LT, Torcia G, Cozzolino F,
Ray A, Tatter SB, Santhanam U, Sehgal PB, Stern D. Interleukin-6 gene
expression in human endothelial cells: RNA start sites, multiple IL-6 proteins
and inhibition of proliferation. Biochem Biophys Res Commun. 1989 Mar
31;159(3):991-8. doi: 10.1016/0006-291x(89)92206-7.
114.
Mohseni Afshar Z, Tavakoli
Pirzaman A, Hosseinzadeh R, Babazadeh A, Taghizadeh Moghadam MA, Miri SR, Sio
TT, Sullman MJM, Barary M, Ebrahimpour S. Anticoagulant therapy in COVID-19: A
narrative review. Clin Transl Sci. 2023 Sep;16(9):1510-1525. doi: 10.1111/cts.13569.
115.
Jarvis GE, Atkinson BT,
Frampton J, Watson SP. Thrombin-induced conversion of fibrinogen to fibrin
results in rapid platelet trapping which is not dependent on platelet
activation or GPIb. Br J Pharmacol. 2003 Feb;138(4):574-83. doi:
10.1038/sj.bjp.0705095.
116.
In response to thrombi, endothelial
cells express and secrete a plethora of proinflammatory proteins, including
monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), interleukin (IL)-1,
interleukin (IL)-6, and interleukin (IL)-8 [221-225]. Through the stimulation
of PAR signalling, the TF-FVIIa complex has the ability to trigger further
release of inflammatory cytokines and chemokines both in vitro and in vivo
[226,227].
117.
Habtemariam, S.
Anti-Inflammatory Therapeutic Mechanisms of Isothiocyanates: Insights from
Sulforaphane. Biomedicines 2024, 12, 1169. https://doi.org/10.3390/biomedicines12061169
118.
Fard MB, Fard SB, Ramazi S,
Atashi A, Eslamifar Z. Thrombosis in COVID-19 infection: Role of platelet
activation-mediated immunity. Thromb J. 2021 Aug 23;19(1):59. doi:
10.1186/s12959-021-00311-9.
119.
Pelle MC, Zaffina I, Lucà S,
Forte V, Trapanese V, Melina M, Giofrè F, Arturi F. Endothelial Dysfunction in
COVID-19: Potential Mechanisms and Possible Therapeutic Options. Life (Basel).
2022 Oct 14;12(10):1605. doi: 10.3390/life12101605.
120.
Brambilla M, Canzano P,
Becchetti A, Tremoli E, Camera M. Alterations in platelets during SARS-CoV-2
infection. Platelets. 2022 Feb 17;33(2):192-199. doi:
10.1080/09537104.2021.1962519.
121.
Hottz ED, Azevedo-Quintanilha
IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR, Righy C, Franco S, Souza TML,
Kurtz P, Bozza FA, Bozza PT. Platelet activation and platelet-monocyte
aggregate formation trigger tissue factor expression in patients with severe
COVID-19. Blood. 2020 Sep 10;136(11):1330-1341. doi: 10.1182/blood.2020007252.
122.
Kaplan MJ, Radic M. Neutrophil
extracellular traps: double-edged swords of innate immunity. J Immunol. 2012
Sep 15;189(6):2689-95. doi: 10.4049/jimmunol.1201719.
123.
Ricklin
D, Reis ES, Lambris JD. Complement in disease: a
defence system turning offensive. Nat Rev Nephrol. 2016 Jul;12(7):383-401. doi:
10.1038/nrneph.2016.70.
124.
Bardhan M, Kaushik R.
Physiology, Complement Cascade. [Updated 2023 Feb 14]. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; 2025
Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551511/
125.
Conway EM, Mackman N, Warren
RQ, Wolberg AS, Mosnier LO, Campbell RA, Gralinski LE, Rondina MT, van de
Veerdonk FL, Hoffmeister KM, Griffin JH, Nugent D, Moon K, Morrissey JH.
Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022 Oct;22(10):639-649.
doi: 10.1038/s41577-022-00762-9.
126.
Riou, M.; Coste, F.; Meyer, A.;
Enache, I.; Talha, S.; Charloux, A.; Reboul, C.; Geny, B. Mechanisms of
Pulmonary Vasculopathy in Acute and Long-Term COVID-19: A Review. Int.
J. Mol. Sci. 2024, 25, 4941. https://doi.org/10.3390/ijms25094941
127.
Guney C, Akar F. Epithelial and
Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes. J Pharm Pharm Sci.
2021;24:84-93. doi: 10.18433/jpps31455.
128.
Varga Z, Flammer AJ, Steiger P,
Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka
F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet.
2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5.
129.
Abou-Ismail MY, Diamond A,
Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence,
pathophysiology, and management. Thromb Res. 2020 Oct;194:101-115. doi:
10.1016/j.thromres.2020.06.029.
130.
Luo HC, You CY, Lu SW, Fu YQ.
Characteristics of coagulation alteration in patients with COVID-19. Ann
Hematol. 2021 Jan;100(1):45-52. doi: 10.1007/s00277-020-04305-x.
131.
Hippensteel JA, Burnham EL,
Jolley SE. Prevalence of venous thromboembolism in critically ill patients with
COVID-19. Br J Haematol. 2020 Aug;190(3):e134-e137. doi: 10.1111/bjh.16908.
132.
Wang
C, Horby PW, Hayden FG, Gao GF. A novel coronavirus
outbreak of global health concern. Lancet. 2020 Feb 15;395(10223):470-473. doi:
10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Feb
15;395(10223):496. doi: 10.1016/S0140-6736(20)30250-6.
133.
Qin C, Zhou L, Hu Z, Zhang S,
Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune
Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin
Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
134.
Campbell S, Greenwood M, Prior
S, Shearer T, Walkem K, Young S, Bywaters D, Walker K. Purposive sampling:
complex or simple? Research case examples. J Res Nurs. 2020 Dec;25(8):652-661.
doi: 10.1177/1744987120927206.
135.
Poissy J, Damonti L, Bignon A,
Khanna N, Von Kietzell M, Boggian K, Neofytos D, Vuotto F, Coiteux V, Artru F,
Zimmerli S, Pagani JL, Calandra T, Sendid B, Poulain D, van Delden C, Lamoth F,
Marchetti O, Bochud PY; FUNGINOS; Allfun French Study Groups. Risk factors for
candidemia: a prospective matched case-control study. Crit Care. 2020 Mar
18;24(1):109. doi: 10.1186/s13054-020-2766-1.
136.
Esposito, G.; Carsana, A.
Metabolic Alterations in Cardiomyocytes of Patients with Duchenne and Becker
Muscular Dystrophies. J. Clin. Med. 2019, 8,
2151. https://doi.org/10.3390/jcm8122151
137.
Tang YW, Schmitz JE, Persing
DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and
Challenges. J Clin Microbiol. 2020 May 26;58(6):e00512-20. doi:
10.1128/JCM.00512-20.
138.
Opal SM, Esmon CT.
Bench-to-bedside review: functional relationships between coagulation and the
innate immune response and their respective roles in the pathogenesis of
sepsis. Crit Care. 2003 Feb;7(1):23-38. doi: 10.1186/cc1854.
139.
Barbour T, Johnson S, Cohney S,
Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol
Dial Transplant. 2012 Jul;27(7):2673-85. doi: 10.1093/ndt/gfs279.
140.
Farooqi F, Dhawan N, Morgan R,
Dinh J, Nedd K, Yatzkan G. Treatment of Severe COVID-19 with Tocilizumab
Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute
Respiratory Distress: A Case Report and Literature Review. Trop Med Infect Dis.
2020 Jul 3;5(3):112. doi: 10.3390/tropicalmed5030112.
141.
Khiali S, Khani E,
Entezari-Maleki T. A Comprehensive Review of Tocilizumab in COVID-19 Acute
Respiratory Distress Syndrome. J Clin Pharmacol. 2020 Sep;60(9):1131-1146. doi:
10.1002/jcph.1693.
142.
de Roquetaillade C, Bredin S,
Lascarrou JB, Soumagne T, Cojocaru M, Chousterman BG, Leclerc M, Gouhier A,
Piton G, Pène F, Stoclin A, Llitjos JF. Timing and causes of death in severe
COVID-19 patients. Crit Care. 2021 Jun 30;25(1):224. doi: 10.1186/s13054-021-03639-w.